Key points from article :
A large observational study led by Sooji Lee at Kyung Hee University in South Korea has found that the shingles vaccine Zostavax is linked to a significantly lower risk of cardiovascular disease. Published in a peer-reviewed journal (not specified), the research analysed health data from over 1.2 million people aged 50 and above, collected between 2012 and 2024.
The study found that individuals who received the Zostavax vaccine were 26% less likely to suffer from stroke, heart attack, heart failure, or death from heart disease, compared to those who were unvaccinated. This protective effect was especially notable in men, younger adults, people with lower incomes, and those living in rural areas. The vaccine’s benefits peaked within two to three years of administration, then gradually declined over five years.
Scientists believe the link may be due to the vaccine preventing the inflammatory effects of shingles, which is known to raise cardiovascular risk shortly after infection. Although the study was observational and can’t prove direct causation, experts say it adds strong support to the idea that vaccinating against shingles may also protect the heart.
The researchers focused on Zostavax due to its longer availability and data history, but are now investigating whether Shingrix, a newer and more effective vaccine, might offer even greater cardiovascular benefits.
